MR Imaging–Based Analysis of Glioblastoma Multiforme: Estimation of IDH1 Mutation Status

BACKGROUND AND PURPOSE: Glioblastoma multiforme is highly aggressive and the most common type of primary malignant brain tumor in adults. Imaging biomarkers may provide prognostic information for patients with this condition. Patients with glioma with isocitrate dehydrogenase 1 (IDH1) mutations have a better clinical outcome than those without such mutations. Our purpose was to investigate whether the IDH1 mutation status in glioblastoma multiforme can be predicted by using MR imaging. MATERIALS AND METHODS: We retrospectively studied 55 patients with glioblastoma multiforme with wild type IDH1 and 11 patients with mutant IDH1. Absolute tumor blood flow and relative tumor blood flow within the enhancing portion of each tumor were measured by using arterial spin-labeling data. In addition, the maximum necrosis area, the percentage of cross-sectional necrosis area inside the enhancing lesions, and the minimum and mean apparent diffusion coefficients were obtained from contrast-enhanced T1-weighted images and diffusion-weighted imaging data. Each of the 6 parameters was compared between patients with wild type IDH1 and mutant IDH1 by using the Mann-Whitney U test. The performance in discriminating between the 2 entities was evaluated by using receiver operating characteristic analysis. RESULTS: Absolute tumor blood flow, relative tumor blood flow, necrosis area, and percentage of cross-sectional necrosis area inside the enhancing lesion were significantly higher in patients with wild type IDH1 than in those with mutant IDH1 (P < .05 each). In contrast, no significant difference was found in the ADCminimum and ADCmean. The area under the curve for absolute tumor blood flow, relative tumor blood flow, percentage of cross-sectional necrosis area inside the enhancing lesion, and necrosis area were 0.850, 0.873, 0.739, and 0.772, respectively. CONCLUSIONS: Tumor blood flow and necrosis area calculated from MR imaging are useful for predicting the IDH1 mutation status.

[1]  S. Choi,et al.  Evaluation of the microenvironmental heterogeneity in high-grade gliomas with IDH1/2 gene mutation using histogram analysis of diffusion-weighted imaging and dynamic-susceptibility contrast perfusion imaging , 2014, Journal of Neuro-Oncology.

[2]  Fang Wang,et al.  An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells , 2013, Science.

[3]  Satoshi O. Suzuki,et al.  Differentiating primary CNS lymphoma from glioblastoma multiforme: assessment using arterial spin labeling, diffusion-weighted imaging, and 18F-fluorodeoxyglucose positron emission tomography , 2013, Neuroradiology.

[4]  P. Kleihues,et al.  The Definition of Primary and Secondary Glioblastoma , 2012, Clinical Cancer Research.

[5]  T. Cloughesy,et al.  Detection of 2-hydroxyglutaric acid in vivo by proton magnetic resonance spectroscopy in U87 glioma cells overexpressing isocitrate dehydrogenase-1 mutation. , 2012, Neuro-oncology.

[6]  Chul-Kee Park,et al.  IDH1 mutation of gliomas with long-term survival analysis. , 2012, Oncology reports.

[7]  M. Mizoguchi,et al.  Associations between microRNA expression and mesenchymal marker gene expression in glioblastoma. , 2012, Neuro-oncology.

[8]  T. Cloughesy,et al.  Relationship between Tumor Enhancement, Edema, IDH1 Mutational Status, MGMT Promoter Methylation, and Survival in Glioblastoma , 2012, American Journal of Neuroradiology.

[9]  A. Beltramello,et al.  Early MRI changes in glioblastoma in the period between surgery and adjuvant therapy , 2012, Journal of Neuro-Oncology.

[10]  Satoshi O. Suzuki,et al.  Arterial spin labeling of hemangioblastoma: differentiation from metastatic brain tumors based on quantitative blood flow measurement , 2012, Neuroradiology.

[11]  Zhaoshi Jiang,et al.  Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Simone Kreth,et al.  O6-Methylguanine-DNA Methyltransferase (MGMT) mRNA Expression Predicts Outcome in Malignant Glioma Independent of MGMT Promoter Methylation , 2011, PloS one.

[13]  D. Kong,et al.  Diagnostic Dilemma of Pseudoprogression in the Treatment of Newly Diagnosed Glioblastomas: The Role of Assessing Relative Cerebral Blood Flow Volume and Oxygen-6-Methylguanine-DNA Methyltransferase Promoter Methylation Status , 2011, American Journal of Neuroradiology.

[14]  W. Reddick,et al.  Quantitative Diffusion-Weighted and Dynamic Susceptibility-Weighted Contrast-Enhanced Perfusion MR Imaging Analysis of T2 Hypointense Lesion Components in Pediatric Diffuse Intrinsic Pontine Glioma , 2011, American Journal of Neuroradiology.

[15]  Satoshi O. Suzuki,et al.  Quantitative digital assessment of MGMT immunohistochemical expression in glioblastoma tissue , 2011, Brain Tumor Pathology.

[16]  M. Perrin,et al.  A Comparative Study of Perfusion Measurement in Brain Tumours at 3 Tesla MR: Arterial Spin Labeling versus Dynamic Susceptibility Contrast-Enhanced MRI , 2010, European Neurology.

[17]  R. McLendon,et al.  IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.

[18]  P. Kleihues,et al.  IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas , 2009, Clinical Cancer Research.

[19]  David T. W. Jones,et al.  IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. , 2009, Neuro-oncology.

[20]  K. Yamashita,et al.  Arterial spin labelling at 3-T MR imaging for detection of individuals with Alzheimer’s disease , 2009, European Radiology.

[21]  F. Ducray,et al.  IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.

[22]  Frank M. Sacks,et al.  IDH 1 and IDH 2 Mutations in Gliomas , 2009 .

[23]  D. Busam,et al.  An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.

[24]  J. Herman,et al.  Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  P. Varlet,et al.  Pulsed arterial spin labeling applications in brain tumors: practical review. , 2008, Journal of neuroradiology. Journal de neuroradiologie.

[26]  K. Aldape,et al.  Identification of noninvasive imaging surrogates for brain tumor gene-expression modules , 2008, Proceedings of the National Academy of Sciences.

[27]  T Sasaki,et al.  Perfusion Imaging of Brain Tumors Using Arterial Spin-Labeling: Correlation with Histopathologic Vascular Density , 2008, American Journal of Neuroradiology.

[28]  S. Y. Kim,et al.  A Prospective Study on the Added Value of Pulsed Arterial Spin-Labeling and Apparent Diffusion Coefficients in the Grading of Gliomas , 2007, American Journal of Neuroradiology.

[29]  P. Kleihues,et al.  Genetic pathways to primary and secondary glioblastoma. , 2007, The American journal of pathology.

[30]  S. Horvath,et al.  Relationship between Survival and Edema in Malignant Gliomas: Role of Vascular Endothelial Growth Factor and Neuronal Pentraxin 2 , 2007, Clinical Cancer Research.

[31]  Toshihiro Kumabe,et al.  Malignant astrocytic tumors: clinical importance of apparent diffusion coefficient in prediction of grade and prognosis. , 2006, Radiology.

[32]  Bahattin Hakyemez,et al.  Evaluation of different cerebral mass lesions by perfusion‐weighted MR imaging , 2006, Journal of magnetic resonance imaging : JMRI.

[33]  S. Franceschi,et al.  Correlation Among Pathology, Genotype, and Patient Outcomes in Glioblastoma , 2006, Journal of neuropathology and experimental neurology.

[34]  M P Lichy,et al.  Diagnostic performance of spectroscopic and perfusion MRI for distinction of brain tumors , 2006, Neurology.

[35]  C. Calli,et al.  Perfusion and diffusion MR imaging in enhancing malignant cerebral tumors. , 2006, European journal of radiology.

[36]  Daniel P Barboriak,et al.  Diffusion-weighted and perfusion MR imaging for brain tumor characterization and assessment of treatment response. , 2006, Radiology.

[37]  Esben Thade Petersen,et al.  Model‐free arterial spin labeling quantification approach for perfusion MRI , 2006, Magnetic resonance in medicine.

[38]  Kaoru Kurisu,et al.  Apparent diffusion coefficient of human brain tumors at MR imaging. , 2005, Radiology.

[39]  R. Gonzalez,et al.  MRI in treatment of adult gliomas. , 2005, The Lancet. Oncology.

[40]  Eytan Domany,et al.  Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes. , 2003, Cancer research.

[41]  C. Zimmer,et al.  Quantification of blood flow in brain tumors: comparison of arterial spin labeling and dynamic susceptibility-weighted contrast-enhanced MR imaging. , 2003, Radiology.

[42]  Wei Zhang,et al.  Molecular Classification of Human Diffuse Gliomas by Multidimensional Scaling Analysis of Gene Expression Profiles Parallels Morphology‐Based Classification, Correlates with Survival, and Reveals Clinically‐Relevant Novel Glioma Subsets , 2002, Brain pathology.

[43]  K. Kono,et al.  The role of diffusion-weighted imaging in patients with brain tumors. , 2001, AJNR. American journal of neuroradiology.

[44]  Scar,et al.  Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. , 2000, The New England journal of medicine.

[45]  J. Detre,et al.  Magnetic resonance perfusion imaging in acute ischemic stroke using continuous arterial spin labeling. , 2000, Stroke.

[46]  J. Detre,et al.  Assessment of cerebral blood flow in Alzheimer's disease by spin‐labeled magnetic resonance imaging , 2000, Annals of neurology.

[47]  Deborah A Yurgelun-Todd,et al.  Differences in cerebellar blood volume in schizophrenia and bipolar disorder , 1999, Schizophrenia Research.

[48]  Toshinori Hirai,et al.  Usefulness of diffusion‐weighted MRI with echo‐planar technique in the evaluation of cellularity in gliomas , 1999, Journal of magnetic resonance imaging : JMRI.

[49]  J. Detre,et al.  Noninvasive MRI evaluation of cerebral blood flow in cerebrovascular disease , 1998, Neurology.

[50]  R D Tien,et al.  MR imaging of high-grade cerebral gliomas: value of diffusion-weighted echoplanar pulse sequences. , 1994, AJR. American journal of roentgenology.

[51]  E. DeLong,et al.  Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. , 1988, Biometrics.